Thai Ho
Hematology & Oncology · Scottsdale, AZNPI 1326054115
Payments from drug & device makers
Across 253 payments — averaging $4969.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$567K
- Merck$528K
- E.r. Squibb & Sons, L.L.C.$50K
- Exelixis Inc.$41K
- Bristol Myers Squibb$22K
- Eisai Inc.$13K
- plus $37K from 22 others
Across 1 payment — averaging $476.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$476
What the payments were for
- Consulting fees$27,90215%
- Speaking & faculty fees$131,30869%
- Travel & lodging$28,50715%
- Food & beverage$2,5611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 44 | $566,812 |
| Merck | 98 | $527,600 |
| E.r. Squibb & Sons, L.L.C. | 6 | $49,952 |
| Exelixis Inc. | 48 | $41,408 |
| Bristol Myers Squibb | 1 | $21,601 |
| Eisai Inc. | 11 | $13,314 |
| Sumitomo Pharma America, Inc. | 4 | $10,348 |
| AstraZeneca | 8 | $7,768 |
| Astrazeneca UK Limited | 1 | $3,280 |
| Sanofi | 6 | $1,965 |
| AVEO Pharmaceuticals, Inc. | 3 | $1,558 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Pfizer | 1 | $1,329 |
| GSK | 2 | $1,300 |
| Taiho Oncology, Inc. | 1 | $1,130 |
| Merck Kgaa | 1 | $1,020 |
| Janssen Scientific Affairs, LLC | 1 | $880 |
| Macrogenics, Inc. | 1 | $800 |
| Daiichi Sankyo Inc. | 2 | $750 |
| Sanofi-aventis U.S. LLC | 2 | $650 |
| Astellas Pharma US Inc | 1 | $500 |
| Immunocore Limited | 1 | $500 |
| Baxter Healthcare | 1 | $400 |
| Athenex Pharmaceutical Division, LLC | 2 | $325 |
| EMD Serono, Inc. | 1 | $255 |
| Caris MPI, Inc. | 3 | $221 |
| Tempus AI, Inc | 1 | $58 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WELIREG$106,855
- Cabometyx$40,592
- LENVIMA$13,244
- IMFINZI$10,704
- FOTIVDA$1,528
- FYARRO$1,500
- INLYTA$1,329
- OJJAARA$1,300
- Lonsurf$1,130
- Erleada$880
- MARGENZA$800
- LIBTAYO$650
- XOSPATA$500
- BioPharma Sol - Research Devel$400
- JEVTANA$350
- BAVENCIO$255
- Oral Paclitaxel$150
- Encequidar$150
- MI CANCER SEEK$107
How this compares
$1,257,235 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $293,406 |
| NubeqaDarolutamide | 22 | $290,112 |
| ErleadaApalutamide | 19 | $217,633 |
| XtandiEnzalutamide | 15 | $186,349 |
| OrgovyxRelugolix | 48 | $126,716 |
| Abiraterone Acetate | 37 | $11,184 |
| EliquisApixaban | 11 | $9,649 |
| Prednisone | 58 | $313 |
| Ondansetron Hcl | 16 | $291 |
| Prochlorperazine Maleate | 15 | $203 |
| Oxycodone Hcl | 13 | $102 |
| Dexamethasone | 11 | $94 |
| Escitalopram Oxalate | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $13,314 | $293,40612 claims |
| Astellas Pharma US IncXtandi | $500 | $186,34915 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $10,348 | $126,71648 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $880 | $11,18437 claims |
| PfizerEliquis | $1,329 | $9,64911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.